Company Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.
Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
The company was incorporated in 2015 and is based in Hamilton, Bermuda.
| Country | Bermuda |
| Founded | 2015 |
| IPO Date | May 24, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 297 |
| CEO | Sanj K. Patel |
Contact Details
Address: Clarendon House, 2 Church Street Hamilton, D0 HM11 Bermuda | |
| Phone | 7814399100 |
| Website | kiniksa.com |
Stock Details
| Ticker Symbol | KNSA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001730430 |
| CUSIP Number | G5269C101 |
| ISIN Number | BMG5269C1010 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sanj K. Patel | Chief Executive Officer and Chairman of the Board |
| Eben Tessari | Senior Vice President and Chief Operating Officer |
| Dr. John F. Paolini | Senior Vice President and Chief Medical Officer |
| Mark Ragosa C.F.A. | Senior Vice President and Chief Financial Officer |
| Michael R. Megna CPA | Chief Accounting Officer and Group Vice President of Finance |
| Mei Jang | Senior Vice President of Technical Operations |
| Rachel Frank | Associate Director of Investor Relations |
| Chad Morin | Senior Vice President and Chief Compliance Officer |
| Madelyn Demsky Zeylikman | SVice President, General Counsel and Secretary |
| Melissa Manno | Senior Vice President and Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2024 | ARS | Filing |
| Apr 23, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 23, 2024 | 8-K | Current Report |
| Apr 10, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 5, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 2, 2024 | 8-K | Current Report |
| Mar 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |